Abstract
Malignant hypercalcemia is defined as the presence of elevated serum calcium concentrations in the context of tumor pathology. It is the most common cause of hypercalcemia in hospitalized patients with solid tumors or hematological malignancies where the postulated mechanisms are the presence of bone metastases and/or the secretion of resorption-activating factors by tumor cells. It can be detected as a finding in the study of asymptomatic patients or associated with severe clinical manifestations that require urgent treatment. The therapeutic approach should be carried out in an interdisciplinary manner aimed at normalizing calcemia, with the etiological diagnosis being important to adapt the therapeutic conduct in the long term, avoiding future complications. This article presents the case of a 43-year-old female patient immunosuppressed by HIV with a diagnosis of symptomatic hypercalcemia in the context of tumor pathology and bone metastases, its multidisciplinary diagnostic and therapeutic approach with a brief review of the subject.
References
David Goltzman. Pathophysiology of Hypercalcemia. Endocrinol Metab Clin N Am 50 (2021) 591–607.
Nateli e Guzano, John Bilezikian. Parathyroid Hormone in the Evaluation of Hypercalcemia JAMA Dic24/31, 2014. Vol312. Num 24.
Trials Humaid Al Farii, Abbey Frazer, Leila Farahdel, Saud Alfayez, and Michael Weber. Zoledronic Acid Versus Denosumab for Prevention of Spinal Cord Compression in Advanced Cancers With Spine Metastasis: A Meta-Analysis of Randomized Controlled Global Spine Journal 2020, Vol. 10(6) 784-789
Jaime Fornetti, Alana L Welm and Sheila A Stewart. Understanding the Bone in Cancer Metastasis. Journal of Bone and Mineral Research, Vol. xx, No. xx, Month 2018, pp 1–15
Peter Donovan et al. PTHrp – Mediated Hypercalcemia: Causes and Survival in 138 patients. JCEM May 2015, 100(5): 2024-2029
Stine Rasch, Thomas Lund, Jon Thor Asmusse, Anne Lerberg Nielsen, Rikke Faebo Larsen, Mikkel Osterheden Andersen and Niels Abildgaard. Multiple Myeloma Associated Bone Disease. Cancers 2020, 12, 2113; doi:10.3390/cancers12082113
Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy. Joshua D. Maier, MD and Steven N. Levine. Journal of Intensive Care Medicine 2015, Vol. 30(5) 235-252
Marlene Chakhtoura, Ghada El-Hajj Fuleihan. Treatment of Hypercalcemia of Malignancy. Endocrinol Metab Clin N Am 50 (2021) 781–792.
Denosumab for treatment of hipercalcemia of Malignancy. Mimi i Hu, et al. JCEM. Sept 2014, 99(9): 2144-3152.
Esta obra está bajo licencia internacional
